In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
about
Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manConvenient Synthesis of Tolcapone, a Selective Catechol‐O‐methyltransferase InhibitorComparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.Post-acquisition analysis of untargeted accurate mass quadrupole time-of-flight MS(E) data for multiple collision-induced neutral losses and fragment ions of glutathione conjugates.Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses.Value of preapproval safety data in predicting postapproval hepatic safety and assessing the legitimacy of class warning.Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicityDrug bioactivation, covalent binding to target proteins and toxicity relevance.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Minimising the potential for metabolic activation in drug discovery.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.Multisubstrate adduct inhibitors: drug design and biological tools.Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disordersMechanisms of drug toxicity and relevance to pharmaceutical development.Bioactivation of herbal constituents: simple alerts in the complex system.Central role of mitochondria in drug-induced liver injury.Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order.Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions.Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?Nitroaromatic compounds: Environmental toxicity, carcinogenicity, mutagenicity, therapy and mechanism.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Cytotoxicity of luteolin in primary rat hepatocytes: the role of CYP3A-mediated ortho-benzoquinone metabolite formation and glutathione depletion.Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites.Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.Bisubstrate Inhibitors of the Enzyme Catechol O-Methyltransferase (COMT): Efficient Inhibition Despite the Lack of a Nitro GroupThe use of structural alerts to avoid the toxicity of pharmaceuticalsDetermination of Entacapone by Differential Pulse Polarography in Pharmaceutical Formulation
P2860
Q28069617-158EB929-0205-41D8-A0DC-E8FB4DE53AD2Q29543109-8E3AC2C0-1AE7-4CE7-8CF6-B9AC37C78089Q30010969-0D63A22A-21B0-457F-899F-45F6FAD002AFQ30868425-EBD97D32-7C0E-4CDB-8D80-7244427C7E5DQ33762518-C3BA70CC-636B-445F-937B-EFF5C840D7F6Q35216989-A40A9405-6672-4E0F-974C-D10864A57F5CQ36040754-B54D194B-0CA6-4EDC-AF90-CA69EA073566Q36061736-C873A4C4-1E18-46B8-8E56-A6810EACBCE3Q36061821-7963A618-7D05-452D-8A23-4C8A4A6A55CFQ36179528-61B5A1CE-D545-49FF-A7BF-87F9CF4DBFEFQ36572637-FD468D28-9474-4595-8F5B-8BF52E39FBA1Q36662857-5F0F8F0B-2D44-4763-A912-006FE9808667Q36662875-FCD017B8-07C7-47BC-A676-84263A40CCF0Q37632419-A994BE3F-D40E-43A6-B2A2-81CB5E0E3226Q37635194-5E5B3ED5-603B-4DF5-9DE3-E376C9908937Q37803316-80F158E8-2E4F-4A52-A3E0-490E8A4C6A3CQ37879144-74279A60-9FF5-48F9-8D76-4B83B0C12827Q37926590-22636EA1-C4DC-4ABD-8747-60934D5B6EE1Q37948134-F11D5C1D-CF90-4C56-AC58-39B64739510AQ38008438-7C49D8DD-8FDF-4D8F-AC78-92FF52028764Q38177342-4080757C-E066-4407-ABED-F658B325C566Q38188523-3156F8BF-BCF3-4B52-8319-74FBF934DA01Q38223072-B8D2B88E-ABB1-4FBD-A8A6-DCEAEEA234EFQ38917549-174CF6B3-EBAE-40BC-A139-EF2C93B19FEAQ46514111-A0B4680C-F303-4EB4-8FAD-D06DB8BAF153Q46959411-69E671E2-5F69-45F1-8619-85850D52696BQ51563626-A8787716-396F-42A0-8CAE-26F8F3D0536FQ57007198-9FCA10D4-B805-41F8-8F8C-AE2F8AB4E475Q57166595-D5AF602A-CFDB-48C1-8EF1-4FBB8F612742Q58159461-0589CB35-BF21-473A-9CAC-1BC37AA3B8A0
P2860
In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@ast
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@en
type
label
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@ast
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@en
prefLabel
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@ast
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@en
P2093
P356
P1476
In vitro metabolism of tolcapo ...... e to tolcapone liver toxicity.
@en
P2093
Joel M Trugman
Kirsten S Smith
Philip L Smith
Tiffany N Heady
Timothy L Macdonald
W Dean Harman
P304
P356
10.1021/TX025569N
P577
2003-02-01T00:00:00Z